Skip to main content

Paget's Disease of Bone

3
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
4 programs
2
1
Zoledronic acidPhase 41 trial
Zoledronic AcidPhase 31 trial
zoledronic acidPhase 31 trial
Genetic Study of Families Affected by Paget's Disease of BoneN/A1 trial
Active Trials
NCT00747994Completed83Est. Sep 2008
NCT00051636Completed172Est. Apr 2011
NCT00103740Completed185Est. Apr 2011
+1 more trials
Novartis
NovartisBASEL, Switzerland
1 program
Genetic Study of Families Affected by Paget's Disease of BoneN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozZoledronic acid
Sandozzoledronic acid
SandozZoledronic Acid
SandozGenetic Study of Families Affected by Paget's Disease of Bone

Clinical Trials (4)

Total enrollment: 449 patients across 4 trials

NCT00774020SandozZoledronic acid

Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)

Start: Oct 2008Est. completion: Jan 20119 patients
Phase 4Completed
NCT00103740Sandozzoledronic acid

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

Start: Apr 2002Est. completion: Apr 2011185 patients
Phase 3Completed
NCT00051636SandozZoledronic Acid

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

Start: Jan 2001Est. completion: Apr 2011172 patients
Phase 3Completed
NCT00747994SandozGenetic Study of Families Affected by Paget's Disease of Bone

Genetic Study of Families Affected by Paget's Disease of Bone

Start: Sep 2007Est. completion: Sep 200883 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.